Sunil Parikh

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa
    S Parikh
    Department of Medicine, San Francisco General Hospital, University of California, San Francisco, USA
    Clin Pharmacol Ther 82:197-203. 2007
  2. pmc Impact of the method of G6PD deficiency assessment on genetic association studies of malaria susceptibility
    Marla K Johnson
    Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 4:e7246. 2009
  3. pmc Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin
    Sunil Parikh
    Department of Medicine, San Francisco General Hospital, University of California, San Francisco, 94110, USA
    Antimicrob Agents Chemother 50:2207-9. 2006
  4. ncbi request reprint Intermittent preventive therapy for malaria in pregnancy: is sulfadoxine-pyrimethamine the right drug?
    S Parikh
    Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA
    Clin Pharmacol Ther 87:160-2. 2010
  5. pmc Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda
    Julia Mwesigwa
    Department of Medicine, 1001 Potrero Avenue, Building 30, Room 3402, University of California, San Francisco, San Francisco, CA 94143 0811, USA
    Antimicrob Agents Chemother 54:52-9. 2010
  6. pmc Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers
    Liusheng Huang
    Drug Research Unit, Department of Clinical Pharmacy, University of California, San Francisco, CA Department of Medicine, University of California, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 61:310-6. 2012
  7. pmc Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors
    Sunil Parikh
    Department of Medicine, San Francisco General Hospital, University of California, San Francisco, Box 0811, San Francisco, California 94110, USA
    Antimicrob Agents Chemother 49:2983-5. 2005
  8. doi request reprint Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers
    Polina German
    Department of Clinical Pharmacy, Drug Research, University of California, School of Medicine, San Francisco, CA 94143 0622, USA
    J Acquir Immune Defic Syndr 51:424-9. 2009
  9. ncbi request reprint Host polymorphisms and the incidence of malaria in Ugandan children
    Sunil Parikh
    Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California, USA
    Am J Trop Med Hyg 71:750-3. 2004
  10. pmc Biochemical and immunological mechanisms by which sickle cell trait protects against malaria
    Lauren Gong
    University of California, Box 1234, San Francisco 94143, CA, USA
    Malar J 12:317. 2013

Research Grants

  1. Host Polymorphisms and Uncomplicated Malaria
    Sunil Parikh; Fiscal Year: 2007

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa
    S Parikh
    Department of Medicine, San Francisco General Hospital, University of California, San Francisco, USA
    Clin Pharmacol Ther 82:197-203. 2007
    ..Variable CYP2C8 activity owing to genetic variation and drug interactions may have important clinical implications for the efficacy and toxicity of AQ...
  2. pmc Impact of the method of G6PD deficiency assessment on genetic association studies of malaria susceptibility
    Marla K Johnson
    Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 4:e7246. 2009
    ..Analyses have been complicated by varied methods used to diagnose G6PD deficiency...
  3. pmc Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin
    Sunil Parikh
    Department of Medicine, San Francisco General Hospital, University of California, San Francisco, 94110, USA
    Antimicrob Agents Chemother 50:2207-9. 2006
    ..As with pepstatin, HIVPIs were equally active against wild-type parasites and against parasites with the food vacuole plasmepsin aspartic proteases knocked out. The antimalarial mechanism of HIVPIs differs from that of pepstatin...
  4. ncbi request reprint Intermittent preventive therapy for malaria in pregnancy: is sulfadoxine-pyrimethamine the right drug?
    S Parikh
    Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA
    Clin Pharmacol Ther 87:160-2. 2010
    ..We discuss IPT with SP in light of several concerns and highlight recent findings from a pharmacokinetic study of SP in this population...
  5. pmc Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda
    Julia Mwesigwa
    Department of Medicine, 1001 Potrero Avenue, Building 30, Room 3402, University of California, San Francisco, San Francisco, CA 94143 0811, USA
    Antimicrob Agents Chemother 54:52-9. 2010
    ..For the artemisinin derivatives, differences between children and adults were variable and drug specific. The PK results generated for children must be considered to optimize the dosing strategies for these widely utilized ACT regimens...
  6. pmc Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers
    Liusheng Huang
    Drug Research Unit, Department of Clinical Pharmacy, University of California, San Francisco, CA Department of Medicine, University of California, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 61:310-6. 2012
    ..A study in healthy volunteers was completed to address the concern that EFV impacts AL pharmacokinetics (PKs)...
  7. pmc Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors
    Sunil Parikh
    Department of Medicine, San Francisco General Hospital, University of California, San Francisco, Box 0811, San Francisco, California 94110, USA
    Antimicrob Agents Chemother 49:2983-5. 2005
    ..Lopinavir also inhibited the P. falciparum aspartic protease plasmepsin II at a similar concentration (IC50, 2.7 microM). These findings suggest that use of HIV-1 protease inhibitors may offer clinically relevant antimalarial activity...
  8. doi request reprint Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers
    Polina German
    Department of Clinical Pharmacy, Drug Research, University of California, School of Medicine, San Francisco, CA 94143 0622, USA
    J Acquir Immune Defic Syndr 51:424-9. 2009
    ....
  9. ncbi request reprint Host polymorphisms and the incidence of malaria in Ugandan children
    Sunil Parikh
    Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California, USA
    Am J Trop Med Hyg 71:750-3. 2004
    ..69, P = 0.05). Host polymorphisms appear to impact upon the incidence of uncomplicated malaria in Ugandan children...
  10. pmc Biochemical and immunological mechanisms by which sickle cell trait protects against malaria
    Lauren Gong
    University of California, Box 1234, San Francisco 94143, CA, USA
    Malar J 12:317. 2013
    ..A better understanding of relevant mechanisms will provide valuable insight into the host-parasite relationship, including the role of the host immune system in protection against malaria. ..
  11. doi request reprint In vitro metabolism of piperaquine is primarily mediated by CYP3A4
    Tina Ming Na Lee
    School of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA 94110, USA
    Xenobiotica 42:1088-95. 2012
    ..Further studies to support these findings through the identification and characterization of PQ metabolites are planned...
  12. pmc Experimental malaria infection triggers early expansion of natural killer cells
    Charles C Kim
    Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA
    Infect Immun 76:5873-82. 2008
    ..These data indicate that the early response to P. chabaudi infection of the blood is marked by a primary wave of interferon with a subsequent response by NK cells...
  13. ncbi request reprint Molecular evaluation of the natural history of asymptomatic parasitemia in Ugandan children
    Sammuel L Nsobya
    Makerere University Medical School, Kampala, Uganda
    J Infect Dis 189:2220-6. 2004
    ..Asymptomatic parasitemia detected by microscopy, but not by PCR, strongly predicted subsequent clinical malaria, often due to persistent infection...

Research Grants2

  1. Host Polymorphisms and Uncomplicated Malaria
    Sunil Parikh; Fiscal Year: 2007
    ..The applicant, Dr. Sunil Parikh, is an infectious disease specialist with a strong commitment to malaria research and international health...